ONC
BeOne Medicines Ltd.
Medical - Pharmaceuticals
Market Cap$33.87B
5Y Perf.+91.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ONC vs MGNX vs RCUS vs ZYME
Revenue, margins, valuation, and 5-year total return — side by side.
MGNX
MacroGenics, Inc.
Biotechnology
Market Cap$186M
5Y Perf.-84.7%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.-20.9%
ZYME
Zymeworks Inc.
Biotechnology
Market Cap$1.98B
5Y Perf.-30.2%
ONC vs MGNX vs RCUS vs ZYME — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ONC | MGNX | RCUS | ZYME |
|---|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $33.87B | $186M | $2.50B | $1.98B |
| Revenue (TTM) | $5.74B | $150M | $236M | $79M |
| Net Income (TTM) | $513M | $-75M | $-369M | $-44.22B |
| Gross Margin | 88.3% | — | 90.7% | 97.9% |
| Operating Margin | 12.0% | -48.7% | -168.6% | -598.4% |
| Forward P/E | 51.9x | — | — | 22.4x |
| Total Debt | $2.00B | $37M | $99M | $18M |
| Cash & Equiv. | $4.55B | $57M | $222M | $41M |
ONC vs MGNX vs RCUS vs ZYME — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ONC
MGNX
RCUS
ZYME
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BeOne Medicines Ltd. (ONC) | 100 | 191.5 | +91.5% |
| MacroGenics, Inc. (MGNX) | 100 | 15.3 | -84.7% |
| Arcus Biosciences, … (RCUS) | 100 | 79.1 | -20.9% |
| Zymeworks Inc. (ZYME) | 100 | 69.8 | -30.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ONC vs MGNX vs RCUS vs ZYME
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ONC leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arcus Biosciences, Inc. is the stronger pick specifically for recent price momentum and sentiment. ZYME also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ONC
BeOne Medicines Ltd.
The Income Pick
ONC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.70
- Rev growth 40.2%, EPS growth 6.4%, 3Y rev CAGR 55.7%
- 10.5% 10Y total return vs ZYME's 104.6%
- 40.2% revenue growth vs RCUS's -4.3%
Best for: income & stability and growth exposure
MGNX
MacroGenics, Inc.
The Secondary Option
MGNX lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
RCUS
Arcus Biosciences, Inc.
The Momentum Pick
RCUS is the #2 pick in this set and the best alternative if momentum is your priority.
- +209.6% vs ONC's +36.5%
Best for: momentum
ZYME
Zymeworks Inc.
The Defensive Pick
ZYME is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.97, Low D/E 6.8%, current ratio 5.52x
- Beta 0.97, current ratio 5.52x
- Better valuation composite
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ONC | 40.2% revenue growth vs RCUS's -4.3% |
| Value | ZYME | Better valuation composite |
| Quality / Margins | ONC | 8.9% margin vs ZYME's -560.8% |
| Stability / Safety | ONC | Beta 0.70 vs RCUS's 1.95 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs ONC's +36.5% |
| Efficiency (ROA) | ONC | 6.7% ROA vs ZYME's -36.9%, ROIC 18.6% vs -25.9% |
ONC vs MGNX vs RCUS vs ZYME — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
ONC vs MGNX vs RCUS vs ZYME — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLONCLAGGINGRCUS
Who Leads Where
ONC leads in 2 of 6 categories
ZYME leads 1 • MGNX leads 0 • RCUS leads 0 • 2 tied
Explore the data ↓RCUSArcus Biosciences, In…
0leads
MGNXMacroGenics, Inc.
0leads
ZYMEZymeworks Inc.
1leads
ONCBeOne Medicines Ltd.
2leads
6 Total Categories
CATEGORYLEADERvs ZYMEvs MGNXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ONC4/6
Valuation MetricsMultiples, price ratios, and targets
ZYME3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ONC7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ONC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ONC is the larger business by revenue, generating $5.7B annually — 72.8x ZYME's $79M. ONC is the more profitable business, keeping 8.9% of every revenue dollar as net income compared to ZYME's -560.8%. On growth, MGNX holds the edge at +132.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ONCBeOne Medicines L… | MGNXMacroGenics, Inc. | RCUSArcus Biosciences… | ZYMEZymeworks Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $5.7B | $150M | $236M | $79M |
| EBITDAEarnings before interest/tax | $948M | -$73M | -$391M | -$47.2B |
| Net IncomeAfter-tax profit | $513M | -$75M | -$369M | -$44.2B |
| Free Cash FlowCash after capex | $846M | -$83M | -$489M | -$45.7B |
| Gross MarginGross profit ÷ Revenue | +88.3% | — | +90.7% | +97.9% |
| Operating MarginEBIT ÷ Revenue | +12.0% | -48.7% | -168.6% | -598.4% |
| Net MarginNet income ÷ Revenue | +8.9% | -49.9% | -156.4% | -560.8% |
| FCF MarginFCF ÷ Revenue | +14.7% | -55.5% | -2.1% | -580.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +35.5% | +132.5% | -39.3% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +2547.0% | +8.0% | +10.5% | -96.7% |
ONC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
ZYME leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, ZYME's 0.3x EV/EBITDA is more attractive than ONC's 53.2x.
| Metric | ONCBeOne Medicines L… | MGNXMacroGenics, Inc. | RCUSArcus Biosciences… | ZYMEZymeworks Inc. |
|---|---|---|---|---|
| Market CapShares × price | $33.9B | $186M | $2.5B | $2.0B |
| Enterprise ValueMkt cap + debt − cash | $31.3B | $166M | $2.4B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | 9.64x | -2.49x | -7.54x | -24.63x |
| Forward P/EPrice ÷ next-FY EPS est. | 51.91x | — | — | 22.43x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 53.20x | — | — | 0.26x |
| Price / SalesMarket cap ÷ Revenue | 6.34x | 1.25x | 10.11x | 18.65x |
| Price / BookPrice ÷ Book value/share | 8.25x | 3.34x | 4.22x | 7.46x |
| Price / FCFMarket cap ÷ FCF | 35.97x | — | — | — |
ZYME leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
ONC leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ONC delivers a 12.1% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-120 for MGNX. ZYME carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to MGNX's 0.66x. On the Piotroski fundamental quality scale (0–9), ONC scores 7/9 vs RCUS's 0/9, reflecting strong financial health.
| Metric | ONCBeOne Medicines L… | MGNXMacroGenics, Inc. | RCUSArcus Biosciences… | ZYMEZymeworks Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.1% | -120.2% | -69.0% | -107.5% |
| ROA (TTM)Return on assets | +6.7% | -29.9% | -35.3% | -36.9% |
| ROICReturn on invested capital | +18.6% | -18.8% | -64.1% | -25.9% |
| ROCEReturn on capital employed | +8.9% | -34.7% | -42.1% | -27.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 | 0 | 5 |
| Debt / EquityFinancial leverage | 0.46x | 0.66x | 0.16x | 0.07x |
| Net DebtTotal debt minus cash | -$2.5B | -$20M | -$123M | -$23M |
| Cash & Equiv.Liquid assets | $4.5B | $57M | $222M | $41M |
| Total DebtShort + long-term debt | $2.0B | $37M | $99M | $18M |
| Interest CoverageEBIT ÷ Interest expense | 17.46x | — | -13.38x | -0.03x |
ONC leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ONC and ZYME each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ONC five years ago would be worth $10,161 today (with dividends reinvested), compared to $924 for MGNX. Over the past 12 months, RCUS leads with a +209.6% total return vs ONC's +36.5%. The 3-year compound annual growth rate (CAGR) favors ZYME at 44.8% vs MGNX's -25.9% — a key indicator of consistent wealth creation.
| Metric | ONCBeOne Medicines L… | MGNXMacroGenics, Inc. | RCUSArcus Biosciences… | ZYMEZymeworks Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.9% | +82.6% | +6.5% | -0.1% |
| 1-Year ReturnPast 12 months | +36.5% | +97.3% | +209.6% | +134.6% |
| 3-Year ReturnCumulative with dividends | +24.8% | -59.4% | +24.9% | +203.7% |
| 5-Year ReturnCumulative with dividends | +1.6% | -90.8% | -18.6% | -12.2% |
| 10-Year ReturnCumulative with dividends | +1045.6% | -84.4% | +45.9% | +104.6% |
| CAGR (3Y)Annualised 3-year return | +7.7% | -25.9% | +7.7% | +44.8% |
Evenly matched — ONC and ZYME each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ONC and ZYME each lead in 1 of 2 comparable metrics.
Risk & Volatility
ONC is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than RCUS's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ZYME currently trades 89.4% from its 52-week high vs MGNX's 75.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ONCBeOne Medicines L… | MGNXMacroGenics, Inc. | RCUSArcus Biosciences… | ZYMEZymeworks Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.70x | 1.93x | 1.95x | 0.97x |
| 52-Week HighHighest price in past year | $385.22 | $3.88 | $28.72 | $29.75 |
| 52-Week LowLowest price in past year | $218.31 | $1.19 | $7.06 | $10.86 |
| % of 52W HighCurrent price vs 52-week peak | +82.3% | +75.8% | +86.3% | +89.4% |
| RSI (14)Momentum oscillator 0–100 | 57.7 | 45.1 | 60.5 | 55.9 |
| Avg Volume (50D)Average daily shares traded | 237K | 1.1M | 1.2M | 612K |
Evenly matched — ONC and ZYME each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ONC as "Buy", MGNX as "Buy", RCUS as "Buy", ZYME as "Buy". Consensus price targets imply 104.1% upside for MGNX (target: $6) vs 21.0% for RCUS (target: $30).
| Metric | ONCBeOne Medicines L… | MGNXMacroGenics, Inc. | RCUSArcus Biosciences… | ZYMEZymeworks Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $401.29 | $6.00 | $30.00 | $38.33 |
| # AnalystsCovering analysts | 13 | 22 | 18 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +2.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
ONC leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZYME leads in 1 (Valuation Metrics). 2 tied.
Best OverallBeOne Medicines Ltd. (ONC)Leads 2 of 6 categories
Loading custom metrics...
ONC vs MGNX vs RCUS vs ZYME: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ONC or MGNX or RCUS or ZYME a better buy right now?
For growth investors, BeOne Medicines Ltd.
(ONC) is the stronger pick with 40. 2% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). BeOne Medicines Ltd. (ONC) offers the better valuation at 9. 6x trailing P/E (51. 9x forward), making it the more compelling value choice. Analysts rate BeOne Medicines Ltd. (ONC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ONC or MGNX or RCUS or ZYME?
On forward P/E, Zymeworks Inc.
is actually cheaper at 22. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ONC or MGNX or RCUS or ZYME?
Over the past 5 years, BeOne Medicines Ltd.
(ONC) delivered a total return of +1. 6%, compared to -90. 8% for MacroGenics, Inc. (MGNX). Over 10 years, the gap is even starker: ONC returned +1046% versus MGNX's -84. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ONC or MGNX or RCUS or ZYME?
By beta (market sensitivity over 5 years), BeOne Medicines Ltd.
(ONC) is the lower-risk stock at 0. 70β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 180% more volatile than ONC relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 66% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ONC or MGNX or RCUS or ZYME?
By revenue growth (latest reported year), BeOne Medicines Ltd.
(ONC) is pulling ahead at 40. 2% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: BeOne Medicines Ltd. grew EPS 637. 4% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, ONC leads at 55. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ONC or MGNX or RCUS or ZYME?
BeOne Medicines Ltd.
(ONC) is the more profitable company, earning 5. 4% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 5. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ONC leads at 8. 4% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ONC or MGNX or RCUS or ZYME more undervalued right now?
On forward earnings alone, Zymeworks Inc.
(ZYME) trades at 22. 4x forward P/E versus 51. 9x for BeOne Medicines Ltd. — 29. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MGNX: 104. 1% to $6. 00.
08Which pays a better dividend — ONC or MGNX or RCUS or ZYME?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ONC or MGNX or RCUS or ZYME better for a retirement portfolio?
For long-horizon retirement investors, BeOne Medicines Ltd.
(ONC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 70), +1046% 10Y return). MacroGenics, Inc. (MGNX) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ONC: +1046%, MGNX: -84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ONC and MGNX and RCUS and ZYME?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ONC is a mid-cap high-growth stock; MGNX is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; ZYME is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ONC: 35.5% · MGNX: 132.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.